Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9523341 | 0.89 | LMNA (0.43) | LMNAKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL9545795 | 0.87 | KMT2A (0.43) | LMNAKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL9568344 | 0.87 | ALDH1A1 (0.43) | LMNAKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL9568297 | 0.87 | KDM4E (0.45) | LMNAKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL9229273 | 0.86 | KMT2A (0.44) | LMNAKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL9229565 | 0.86 | KMT2A (0.44) | LMNAKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL9568806 | 0.86 | LMNA (0.41) | LMNAKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL9234886 | 0.85 | KMT2A (0.43) | LMNAKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL9568347 | 0.85 | PRKCZ (0.43) | LMNAKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL9522285 | 0.85 | LMNA (0.57) | LMNAKMT2AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009093268-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE PRULIFLOXACIN | IND-SWIFT LABORATORIES LIMITED (IN) | 2009-07-30 | — | — | WO | claimed |
| WO-2012001357-A1 | CRYSTALLINE FORM OF PRULIFLOXACIN AND PROCESSES FOR ITS PREPARATION | CIPLA LIMITED (IN) | 2012-01-05 | — | — | WO | disclosed |
| CN-101857602-B | Preparation method for Prulifloxacin | Hunan ouya biology co ltd | 2011-11-09 | — | — | CN | disclosed |
| CN-101857602-A | Preparation method for Prulifloxacin | HUNAN OUYA BIOMEDICAL CO LTD | 2010-10-13 | — | — | CN | disclosed |
| US-20100197910-A1 | PROCESS FOR PREPARATION OF PRULIFLOXACIN USING NOVEL INTERMEDIATES | HETERO DRUGS LIMITED (IN) | 2010-08-05 | — | — | US | disclosed |
| US-20100197910-A1 | PROCESS FOR PREPARATION OF PRULIFLOXACIN USING NOVEL INTERMEDIATES | HETERO DRUGS LIMITED (IN) | 2010-08-05 | — | — | US | disclosed |
| WO-2009093268-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE PRULIFLOXACIN | IND-SWIFT LABORATORIES LIMITED (IN) | 2009-07-30 | — | — | WO | disclosed |
| EP-2081940-A1 | PROCESS FOR PREPARATION OF PRULIFLOXACIN USING NOVEL INTERMEDIATES | Hetero Drugs Limited (IN) | 2009-07-29 | — | — | EP | disclosed |
| EP-2081940-A1 | PROCESS FOR PREPARATION OF PRULIFLOXACIN USING NOVEL INTERMEDIATES | Hetero Drugs Limited (IN) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008059512-A1 | PROCESS FOR PREPARATION OF PRULIFLOXACIN USING NOVEL INTERMEDIATES | HETERO DRUGS LIMITED (IN) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059512-A1 | PROCESS FOR PREPARATION OF PRULIFLOXACIN USING NOVEL INTERMEDIATES | HETERO DRUGS LIMITED (IN) | 2008-05-22 | — | — | WO | disclosed |
| EP-0878194-A1 | REMEDIES OR PREVENTIVES FOR AIDS | SANKYO COMPANY LIMITED (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5688791-A | COMPOUNDS FOR TREATMENNT OF VIRAL DISEASES SUCH AS AIDS | UBE INDUSTRIES, LTD. (JP) | 1997-11-18 | — | — | US | disclosed |
| EP-0249043-B1 | QUINOLINECARBOXYLIC ACID DERIVATIVES | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5126337-A | Wide-spectrum bactericides | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1992-06-30 | — | — | US | disclosed |
| US-5086049-A | Bactericides | NIPPONSHINYAKU CO., LTD. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0465716-A1 | Optically active thiazetoquino-line-3-carboxylic acid compound, method for preparation thereof, and a pharmaceutical composition comprising the same | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1992-01-15 | — | — | EP | disclosed |
| EP-0393538-A2 | Thiazetoquinoline-3-Carboxylic acid derivative, method for preparation thereof, and a pharmaceutical composition comprising the same | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4843070-A | BACTERIDCIDES, FUNGICIDES | NIPPON SHINYAKU CO., LTD. (JP) | 1989-06-27 | — | — | US | disclosed |
| EP-0249043-A2 | Quinolinecarboxylic acid derivatives | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1987-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197910-A1 | PROCESS FOR PREPARATION OF PRULIFLOXACIN USING NOVEL INTERMEDIATES | KCNH1, QDPR, DPYD | LMNA 3268/4885KMT2A 477/4885KDM4E 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.